3-(3-羟基-2-甲基-4-氧代吡啶-1-基)丙酸乙酯 | 95215-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(3-羟基-2-甲基-4-氧代吡啶-1-基)丙酸乙酯
• 英文名称: 1(4H)-Pyridinepropanoic acid, 3-hydroxy-2-methyl-4-oxo-, ethyl ester
• 英文别名: ethyl 3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanoate
• CAS: 95215-60-4
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: SIPVUGNHQRPDCV-UHFFFAOYSA-N

物化性质

• 沸点：
  353.8±42.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  麦芽醇 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 58.0h， 生成 3-(3-羟基-2-甲基-4-氧代吡啶-1-基)丙酸乙酯
  参考文献：
  名称：

  N-取代的-2-烷基-3-羟基-4（1H）-吡啶酮的合成，理化性质和评价。

  摘要：

  描述了一系列可能与铁（III）螯合的3-羟基-4（1H）-吡啶酮的合成。给出了各个配体的pKa值及其铁（III）配合物的稳定性常数。报告了1-辛醇和MOPS缓冲液（pH 7.4）之间48种羟基吡啶酮及其对应的铁（III）配合物的分布系数值。对数Dcomplex值的范围涵盖7个数量级。结果表明，螯合剂的分布系数值与相应的铁（III）配合物之间存在两相关系。对于对数Dligand = -1的配体，线性关系的斜率值为2.53，而对于对数Dligand <-1的配体，线性关系的斜率为0.49。该系列的亲水性更高的分子的降低的斜率为这种类型的羟基吡啶酮提供了一些优势，因为此类配合物的分配系数不会随着配体亲水性的增加而迅速改变。在非铁超负荷，胆管插管的大鼠和[59Fe]铁蛋白负荷的大鼠模型中，研究了选定的3-羟基吡啶酮促进胆汁中铁的排泄的能力。两种系统都比较了螯合剂从肝脏（地中海贫血的主要靶器官）中去

  DOI：

  10.1021/jm9707784

文献信息

• Iron III complexes of hydroxypyridones, and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0120670A1

  公开（公告）日：1984-10-03

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, are of value for the treatment of iron deficiency anaemia.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮铁络合物的药物组合物，其中与氮原子相连的氢原子被脂肪族酰基、脂肪族烃基或被一个或一个以上取代基取代的脂肪族烃基所取代（可电离基团除外），取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、在可离子化基团的情况下，一个以上选自脂肪族酰基、烷氧基、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和磺基的取代基，以及环碳原子上的一个或多个氢原子被上述取代基、脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基取代，但不包括化合物中的氢原子仅被脂肪族烃基取代的化合物，这些化合物具有治疗缺铁性贫血的价值。
• Hydroxypyridones, and their pharmaceutical compositions
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0120669A2

  公开（公告）日：1984-10-03

  Pharmaceutical compositions containing a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by aliphatic hydrocarbon groups, or a saltthereof containing a physiologically acceptable ion or ions, are of value for removing toxic amounts of metals, particularly iron, from the body.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮的药物组合物，其中与氮原子相连的氢原子被脂族酰基、脂族烃基取代、或被一个或一个以上取代基取代的脂肪族烃基，这些取代基选自脂肪族酰基、烷氧基、脂肪族胺、脂肪族酰胺、羧基、脂肪族酯、卤素、羟基和亚砜基，可选的情况除外、其中与环碳原子相连的一个或多个氢原子被上述取代基之一、脂肪族烃基或被烷氧基、脂肪族酯、卤素或羟基取代的脂肪族烃基所取代，但不包括化合物中的氢原子仅被脂肪族烃基取代的化合物，或含有生理上可接受的一种或多种离子的盐。
• 3-Hydroxypyrid-4-ones and pharmaceutical compositions
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0305646A2

  公开（公告）日：1989-03-08

  Pharmaceutical compositions containing a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, aliphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by substituents selected from aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy group or groups, or a physiologically acceptable salt thereof, are of value for removing toxic amounts of metals, particularly iron, from the body.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮的药物组合物，其中与氮原子相连的氢原子被脂族酰基、脂族烃基或被选自脂族酰基、脂族酰胺、脂族酯、卤素和羟基的一个或多个取代基取代，并且可选地，其中与环碳原子相连的一个或多个氢原子被上述取代基之一取代、脂族烃基，或被烷氧基、脂族酯、卤素或羟基取代的脂族烃基，但不包括仅由选自脂族烃基和被一个或多个烷氧基取代的脂族烃基的取代基实现化合物中氢原子的取代的化合物，或其生理上可接受的盐。
• US4585780A
  申请人：——

  公开号：US4585780A

  公开（公告）日：1986-04-29
• US4650793A
  申请人：——

  公开号：US4650793A

  公开（公告）日：1987-03-17